Provectus Appoints Dr. Joseph M. Chalil to Strategic Advisory Board
March 19 2014 - 6:05AM
Business Wire
Associate Director, Health Science Executive of Boehringer
Ingelheim; Co-Chair, AAPI Industry Physician Committee and
Scientific Advisor to AAPI; Fellow of American College of
Healthcare Executives; Has 15 Years’ Experience in Healthcare
Marketing, Sales and Business Development
Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT),
http://www.pvct.com, a development-stage oncology and dermatology
biopharmaceutical company, announced that it has appointed Dr.
Joseph M. Chalil, MD, MBA, FACHE, to its Strategic Advisory
Board.
Dr. Chalil is Associate Director, Health Science Executives of
Boehringer Ingelheim, the world’s largest privately held
pharmaceutical company. Headquartered in Ingelheim, Germany, the
company operates globally in more than 50 countries. In 2012,
Boehringer Ingelheim achieved net sales of 19.1 billion (USD);
R&D expenditure in the business area of prescription medicines
reached a quarter of its net sales.
In addition to his responsibilities at Boehringer Ingelheim, Dr.
Chalil is the Co-Chair for the Industry Physician Committee of the
American Association of Physicians of Indian Origin (AAPI) and has
served as Scientific Advisor to AAPI for the past three years. AAPI
is the second largest physician organization in the US second only
to AMA, and the largest ethnic medical organization in the
country.
A veteran of the United States Navy Medical Corps, Dr. Chalil is
also board certified in healthcare management, and has been awarded
Fellowship by the American College of Healthcare Executives, an
international professional society of more than 40,000 healthcare
executives who lead hospitals, healthcare systems and other
healthcare organizations.
Dr. Chalil is an expert in US Healthcare policy and a strong
advocate for patient centered care, and has also served as an
advisor to various national political campaigns on healthcare
issues.
As the former CEO of Clinical Consultants International, he
represented prominent healthcare companies, including GE
Healthcare, Genpact, HIRCO Group, Godrej Ltd, KLE University,
Somaiya Group, Pushpanjali Crosslay Hospital, Excel Life Sciences
and various international pharmaceutical firms over the past
decade.
Dr. Chalil completed his higher studies in University of
Medicine and Dentistry of New Jersey, Davenport University, JJM
Medical College and Baylor College of Medicine. He has been a
Visiting Professor at various Universities and serves on various
company Boards.
Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals said,
“Adding Dr. Chalil to our Strategic Advisory Board will strengthen
our collective expertise in healthcare marketing, sales and
business development. His depth and breadth of experience in these
fields will enable Provectus to take greater advantage of the
opportunities that lie ahead.”
Dr. Chalil said, “I am honored to join the Provectus Strategic
Advisory Board at this critical juncture of the company’s
development as it brings PV-10 and other treatments through the
developmental regulatory approval processes.”
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology
and dermatology therapies. Its novel oncology drug PV-10 is
designed to selectively target and destroy cancer cells without
harming surrounding healthy tissue, significantly reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. Its dermatological drug PH-10
also targets abnormal or diseased cells, with the current focus on
psoriasis and atopic dermatitis. Provectus has recently completed
Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and
of PH-10 as a topical treatment for atopic dermatitis and
psoriasis. Information about these and the Company's other clinical
trials can be found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus please visit the
Company's website at www.pvct.com or contact Porter, LeVay &
Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements
contained herein are subject to certain risks and uncertainties
that could cause actual results to differ materially from those
reflected in the forward-looking statements. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which reflect management's analysis only as of the date hereof. The
company undertakes no obligation to publicly revise these
forward-looking statements to reflect events or circumstances that
arise after the date thereof.
MULTIMEDIA AVAILABLE:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50819566&lang=en
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper,
866-594-5999 #30CFO, COOorPorter, LeVay & Rose, Inc.Marlon
Nurse, 212-564-4700DM, SVP – Investor RelationsofBill Gordon,
212-724-6312Media Relations
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024